<DOC>
	<DOCNO>NCT02724228</DOCNO>
	<brief_summary>This Phase 2 , Open-Label , Extension Study Evaluate Long-Term Safety , Tolerability , Efficacy BMN 111 Children Achondroplasia . The primary objective evaluate long-term safety tolerability daily SC injection BMN 111 child ACH complete two year treatment 111-202 study .</brief_summary>
	<brief_title>A Study Evaluate Long-Term Safety , Tolerability , &amp; Efficacy BMN 111 Children With Achondroplasia ( ACH )</brief_title>
	<detailed_description />
	<mesh_term>Achondroplasia</mesh_term>
	<mesh_term>Natriuretic Peptide , C-Type</mesh_term>
	<criteria>Have complete 24 month BMN 111 treatment Study 111202 . Parent ( ) guardian ( ) willing able provide write , sign informed consent . If sexually active , willing use highly effective method contraception participate study . Willing able perform study procedure physically possible Parents/caregivers willing administer daily injection subject complete require training . Requires investigational agent prior completion study period . Have condition circumstance , view Investigator , place subject high risk poor treatment compliance complete study . Concurrent disease condition , view Investigator , would interfere study participation safety evaluation reason . Permanently discontinue BMN 111 111202 study . Subject pregnant . Current chronic therapy restrict medication .</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Achondroplasia</keyword>
	<keyword>Dwarfism</keyword>
	<keyword>Bone Diseases , Developmental</keyword>
	<keyword>Bone Diseases</keyword>
</DOC>